Vaccine Scheduler

Pneumococcal Disease: Recommended vaccinations

	General recommendation
	Recommendation for specific groups only
	Catch-up (e.g. if previous doses missed)
	Vaccination not funded by the National Health system
	Mandatory vaccination

	Weeks	Months												Years
	6	2	3	4	5	6	10	11	12	13	14	15	18	2	17	18	50	59	60	64	65	≥ 75
Austria	PCV15¹			PCV15				PCV15								PCV21²			PCV21²

Belgium		PCV13 or PCV20³		PCV13 or PCV20³					PCV13 or PCV20³							PCV20					PCV20 or PCV21

Bulgaria		PCV⁴		PCV⁴					PCV⁵												PCV13⁶

Croatia		PCV10 or PCV13		PCV10 or PCV13					PCV10 or PCV13							PCV15+PPSV23⁷

Cyprus			PCV15 or PCV20		PCV15 or PCV20				PCV15 or PCV20⁸							PCV20					PCV20

Czechia		PCV	PCV			PCV⁹				PCV						PCV20 or PCV21¹⁰					PCV20 or PCV21

Denmark			PCV15		PCV15				PCV15

Estonia																PCV13/PCV15 + PPSV23 or PCV20¹¹						PCV13 or PCV15 or PCV20 or PPSV23

Finland			PCV10		PCV10				PCV10							PCV20¹²

France		PCV13 or PCV15		PCV13 or PCV15				PCV13 or PCV15								PCV20					PCV20

Germany		PCV13 or PCV15		PCV13 or PCV15				PCV13 or PCV15						PCV13/15+PPSV23		PCV20			PCV20

Greece		PCV15 or PCV20		PCV15 or PCV20					PCV15 or PCV20¹³							PCV20					PCV20

Hungary		PCV15		PCV15					PCV15							PCV15+PPSV23 or PCV20					PCV20

Iceland			PCV15		PCV15				PCV15							PCV15+PPSV23 or PCV20¹⁴			PCV20 or PPSV23¹⁴

Ireland		PCV13 or PCV15				PCV13 or PCV15				PCV13 or PCV15				PPSV23¹⁵

Italy		PCV13		PCV13			PCV13									PCV13+PPSV23					PCV13+PPSV23¹⁶

Latvia		PCV13 or PCV15¹⁷		PCV13 or PCV15					PCV13 or PCV15							PCV13 or PCV15 or PCV20					PCV13 or PCV15 or PCV20

Liechtenstein		PCV13 or PCV15		PCV13 or PCV15					PCV13 or PCV15							PCV15 or PCV20					PCV15 or PCV20

Lithuania		PCV15		PCV15					PCV15¹⁸					PCV20¹⁹							PCV20

Luxembourg		PCV10 or PCV13	PCV²⁰	PCV10 or PCV13				PCV10 or PCV13				PCV²¹				PCV20²²					PCV20²³

Malta		PCV10		PCV10					PCV10							PCV20²⁴

Netherlands			PCV15		PCV15				PCV15										PCV20²⁵

Norway			PCV13		PCV13				PCV13							PCV20 or PCV21 and PPSV23²⁶					PCV20 or PCV21 and PPSV23

Poland		PCV10		PCV10						PCV10							PCV13+PPSV23				PCV13+PPSV23

Portugal		PCV20²⁷		PCV20²⁷					PCV20²⁷					PPSV23²⁸		PCV20+PPSV23²⁸					PPSV23²⁸

Romania		PCV13		PCV13				PCV13								PCV13/PCV15 + PPSV23 or PCV20					PCV13 or PCV15 or PCV20 or PPSV23

Slovakia			PCV10 or PCV13 or PCV15		PCV10 or PCV13 or PCV15			PCV10 or PCV13 or PCV15²⁹										PCV³⁰

Slovenia			PCV20		PCV20	PCV20		PCV20								PCV20					PCV20

Spain		PCV13 or PCV15 or PCV20³¹		PCV13 or PCV15 or PCV20				PCV13 or PCV15 or PCV20								PCV13/15+PPSV23³²					PCV13/15+PPSV23³³

Sweden			PCV15		PCV15				PCV15							PCV20 or PPSV23³⁴						PPSV23³⁵

Footnotes:

Vaccination with PCV15 as soon as possible after the age of 6 weeks, and no later than the age of 3 months. Second dose is given 8 weeks after the first dose, and third dose at the age of 11–15 months (at the earliest 6 months after the second dose). For children without specific indications, vaccination is not recommended after the age of 5. More information: https://impfen.gv.at/impfungen/pneumokokken or https://www.sozialministerium.gv.at/impfplan (p. 93ff)
Vaccination recommended and free of charge for people aged 60 and over and for certain high-risk individuals aged 18 and over. Persons aged 60 years and older who have previously been vaccinated with another pneumococcal vaccine should receive a single dose of PCV21 after approximately 1 year for broader serotype coverage. Even if they have previously been vaccinated sequentially (PCV13/PCV15/PCV20 followed by PPV23), a single booster dose of PCV21 should be given, with the recommended interval being at least 1 year (for PCV13/15 followed by PPV23) and no more than 6 years (PCV20 followed by PPV23) after the last dose. More information: https://www.sozialministerium.gv.at/impfplan (p. 95ff)
PCV20 is recommended but not implemented in the free routine vaccination programs. For infants, free vaccination with PCV13 (2-4-12m) is offered by the federated entities
Routine vaccination begins at 6 weeks of age. Second dose is given at 14 weeks of age. For children born to mothers vaccinated against pertussis during pregnancy, mandatory immunization against pneumococcal infections is carried out from two months of age. Subsequent immunization is administered no earlier than 8 weeks after the first dose, respectively from four months of age.
Not earlier than 6 months after the previous dose.
For people over 65 years of age influenza and pneumococcal vaccines and administration are free of charge and funded according to the National programme.
PPSV23 alone is also an option depending on the medical conditions.
When PCV20 is used, the recommended schedule consists of 3 primary doses + 1 booster dose (3+1).
Third dose if PCV20 used.
PCV20 or PCV21. Vaccination covered from the National Health system for individuals of age 65 and older, and for individuals with impaired/absent splenic function (hyposplenism or asplenia), or with an indicated or previously performed splenectomy; individuals who have undergone autologous or allogeneic hematopoietic stem cell transplantation; individuals with severe primary or secondary immunodeficiencies requiring follow-up care at a specialized center; individuals with a history of IMO or IPO. Also covered for individuals in long-term care hospitals, in nursing homes for seniors, in residential facilities for persons with disabilities or in facilities with a special care regime, provided that these individuals suffer from chronic non-specific respiratory diseases, chronic diseases of the heart, blood vessels, or kidneys, or from diabetes treated with insulin.The vaccination is recommended also for people 18+ with risk factors. For details see: https://www.vakcinace.eu/doporuceni-a-stanoviska/doporuceni-cvs-cls-jep-pro-ockovani-dospelych-proti-pneumokokovym-onemocnenim
Risk groups list is published here: https://terviseamet.ee/sites/default/files/documents/2024-07/pneumo-_ja_meningokokk-nakkuse_korge_riskiga_riskiruhmad.pdf
for more information on pneumococcal vaccination and target groups refer to https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/pneumokokkirokotteet/riskiryhmien-pneumokokkirokotukset
When PCV20 is selected, the recommended schedule consists of 3 primary doses + 1 booster dose (3+1).
Recommendation without funding. Details https://island.is/en/bolusetning-gegn-pneumokokkum
Please refer to https://www.hse.ie/eng/health/immunisation/pubinfo/adult/pneumo/#Who%20should%20be%20vaccinated%20with%20PPV23%20Pneumococcal%20vaccine? for a full listing of people in at-risk groups
one dose of PCV13 at 65 years and one dose PPSV after at least 8 weeks
https://www.vm.gov.lv/lv/media/11925/download?attachment
Can be administered concomitantly with MMR
Vaccination is recommended for unvaccinated children and adults younger than 65 years of age with underlying conditions.
For premature infants (born before 33 weeks) or with a birthweight <1500g, a 3+1 schedule is recommended
For those not previously vaccinated with an increased risk of severe disease.
for those at increased risk of complications or severe disease
For people aged 65 years of age, update to the pneumococcal recommendations based on prior vaccination. please refer to the full recommendation available here: https://sante.public.lu/dam-assets/fr/espace-professionnel/recommandations/conseil-maladies-infectieuses/infection-pneumocoques/csmi-recommandation-vaccination-pcv-personnes-agees-ou-a-risque.pdf
PCV20 is also recommended for children with specific medical conditions instead of PCV 10. If PCV 10 was already administered as a full course, then a single PCV20 booster dose is offered.
PCV20 is offered to 60 year old individuals and to people above 60 years of age (five years after their previous invitation for PPV23). In some circumstances, it can also be prescribed to medical high risk groups below 60 years of age by the attending medical doctor and reimbursed by the health insurer. (https://lci.rivm.nl/factsheets/pneumokokkenvaccinatie)
Fully funded for patients with HIV infections, stem cell transplantations and for anatomical or functional asplenia. Partly funded when turning 65 years. Not funded (NF) for other risk groups. More information: https://www.fhi.no/en/va/vaccines-for-adults/vaccines-in-the-adult-immunisation-programme/vaccines-in-the-adult-immunisation-programme/pneumococcal-vaccine-information-for-the-public/
PCV20 recommended at 2, 4 and 12 months of age. More information available at: https://www.dgs.pt/ficheiros-de-upload-2013/19-doenca-pneumococica-pdf.aspx
More information on which groups have free access to the vaccination available at: https://www.dgs.pt/ficheiros-de-upload-2013/19-doenca-pneumococica-pdf.aspx
https://www.ockovaniechrani.sk/#/ockovaci-kalendar
Vaccination is also mandatory for persons placed in social service facilities. Vaccination is recommended for persons under medical supervision, regardless of age, with serious chronic diseases of the respiratory tract, cardiovascular system, metabolic, renal and immune disorders, persons with functional or anatomical asplenia prior to splenectomy, and persons 59 years of age and older. https://www.uvzsr.sk/web/uvz/povinne-a-odporucane-ockovanie-podla-dosiahnuteho-veku-a-rizika-nakazy-v-slovenskej-republike-na-rok-2016
More information: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/calendario/docs/CalendarioVacunacion_Todalavida.pdf
PPSV or sequential schedule (PCV+PPSV) depend on pathology and available vaccines.
PCV is recommended in some regions.
More information: https://www.folkhalsomyndigheten.se/publikationer-och-material/publikationsarkiv/r/rekommendationer-om-pneumokockvaccination-/
https://www.folkhalsomyndigheten.se/smittskydd-beredskap/vaccinationer/nationella-vaccinationsprogram/program-for-riskgrupper/